Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

482 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    China | Market Exclusivity And Data Exclusivity Included In Drug Administration Law Revisions

    Marking a milestone in China's drug regulatory landscape, the 2026 Revisions of China's Drug Administration Law introduce data exclusivity and market exclusivity into the regulatory framework...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Spruson & Ferguson Lawyers
    Spruson & Ferguson Lawyers
  • Article

    Generic Drugs

    Supply of generic drugs and their interaction with the patent system, like standards essential patents, present one of the international frontiers of patent protection.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Toby Mak
    Toby Mak
Article

Rules For The Implementation Of The Patent Law And Guidelines For Patent Examination

On 21 December 2023, after more than two years of revisions, the China National Intellectual Property Administration (CNIPA) issued the finalized version of the revised Rules for the Implementation of the Patent Law, as well as the Guidelines for Patent Examination.
ChinaIntellectual Property
HFG Law & Intellectual Property
HFG Law & Intellectual Property
  • Article

    【华源原创】专利查新检索能否代替专利侵权风险排查?

    根据《二〇二一年中国知识产权保护状况》白皮书,2021年全国地方各级人民法院新收知识产权一审案件550263件,审结515861件,其中新收专利案件31618件,
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    A Closer Look At China's New E-Cigarette Regulations

    With the implementation of the Management Rules of E-cigarettes and the forthcoming effective date for the GB Standard on E-cigarettes (October 1, 2022), China has been regularly updating its e-cigarette regulations.
    GlobalFood, Drugs, Healthcare, Life Sciences
    Keller & Heckman
    Keller & Heckman
  • Article

    Overview Of Recent Anti-Corruption Enforcement Actions In The Pharmaceutical Industry In China

    On May 8, 2023, the National Health Commission of the People's Republic of China (the "PRC"), along with 13 other government departments...
    ChinaCriminal Law
    Sheppard
    Sheppard
  • Article

    [Food Law] Defects In Writing Food Label Can Lead To A Lawsuit

    An eighteen years old professional complainant in Guangdong province raised over 800 complains and suits in one year.
    ChinaFood, Drugs, Healthcare, Life Sciences
    HFG Law & Intellectual Property
    HFG Law & Intellectual Property
  • Article

    4th Amendments To The Chinese Patent Law

    Major improvements are on design patent, and patent infringement compensation.
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    China FDA Calls For Comments On Key Policy Proposals

    Further legislative initiatives will be arranged if any parts of the draft policies contradict the current CFDA regulations.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    China's Draft Patent Linkage Implementation Method For Public Comment

    This Method is drafted by China's National Medical Products Administration in conjunction with the China National IP Administration, and was published for public's comments on 11 September 2020 in the link below.
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    China IP Updates: April 2022 (Issue 1)

    According to the Notice of CNIPA on Continuing to Severely Crack Down on Malicious Registration of Trademarks (hereinafter referred to as the "Notice"),..
    ChinaIntellectual Property
    Rouse
    Rouse
  • Article

    Draft Revisions To The CN Patent Examination Guidelines (Aug 2021) - Toby's Views

    On 3 August 2021, the CNIPA published yet another draft revisions to the CN Patent Examination Guidelines (the Guidelines).
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    Main Points Of Proposed Amendment (4th) To Chinese Patent Law

    China's National People's Congress (NPC) has recently published an updated Draft of Proposed Amendment to Chinese Patent Law.
    ChinaIntellectual Property
    China Sinda Intellectual Property Ltd
    China Sinda Intellectual Property Ltd
  • Article

    Promoting Innovation With Enhanced Protection And Enforcement Measurements Under New Chinese Patent Law

    On October 17, 2020, the Standing Committee of the National People's Congress of China approved the new Chinese Patent Law, which will become effective on June 1, 2021.
    ChinaIntellectual Property
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Patenting Medical Use Inventions In China

    A medical use of a product may relate to i) the use of a new drug to treat a disease ("first medical use"); ii) the use of a known drug to treat a new disease...
    ChinaFood, Drugs, Healthcare, Life Sciences
    CCPIT Patent and Trademark Law Office
    CCPIT Patent and Trademark Law Office
  • Article

    Discussion On Donation Rules And Estoppel Rules As Well As Practical Suggestions For Implementation

    This article aims to introduce the constraining impacts of donation rules and estoppel rules on the scope of protection of patent claims, and offer pertinent suggestions...
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    FINAL - CN First Drug Patent Linkage Appeal Decided

    Thanks again for the heads up from Aaron Wininger of Schwegman Lundberg & Woessner, the China Supreme Court (the Supreme Court) has decided on the appeal of this first drug patent linkage decision, which is final.
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    Interpretation Of The Revised 'Regulations For The Implementation Of The Drug Administration Law' And Compliance Implications

    In January 2026, the State Council promulgated the revised Regulations for the Implementation of the Drug Administration Law of the People's Republic of China...
    ChinaIntellectual Property
    Chang Tsi & Partners
    Chang Tsi & Partners
  • Article

    Restrictions And Conflicts – Challenges Faced By Pharmaceutical Trademarks In China

    Trademarks represent one of the most essential competitive and strategic assets of a company. When considering how consumers identify their choices among other alternatives, trademarks are key
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    Thin Disclosure But "Bulletproof" Protection: How A Salt Form Patent Was Upheld In China Despite Minimal Data

    In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors.
    ChinaIntellectual Property
    Eagle IP
    Eagle IP
  • Showing 221–240 of 482 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics